The Latest Analyst Ratings for ALX Oncology Holdings
Portfolio Pulse from Benzinga Insights
ALX Oncology Holdings (NASDAQ:ALXO) received 7 analyst ratings in the last quarter, with an average 12-month price target of $17.79, a high of $27.00, and a low of $10.00. The current average price target represents an 8.48% increase from the previous average of $16.40. The distribution of ratings was 3 bullish, 4 somewhat bullish, and no indifferent, somewhat bearish, or bearish ratings. Analysts typically rate stocks each quarter based on various research methods and their ratings reflect their opinions on the stock.
November 14, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ALX Oncology Holdings has received a positive outlook from analysts with an increased average price target of $17.79, suggesting a bullish sentiment among analysts.
The increase in the average price target and the predominance of bullish over bearish ratings indicate a positive sentiment among analysts, which could lead to short-term price appreciation. The confidence in this analysis is high due to the clear consensus among analysts and the recent update in the price target.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100